ThermoFisher-Qiagen deal off

- Thermo Fisher has a revenue of $24B

- Qiagen is a molecular diagnostics company

- originally $11,5B deal

- couldn't find the shareholder support - only 47 % out of 66 % needed shares were tendered

Source: Medtechdive

Read more:

#medicaldevices #mergersandacquisitions #moleculardiagnostics

2 views0 comments

Recent Posts

See All

As seen by Harvard Health Publishing in 2020, these trends in cardiology play may play a vital role in the upcoming decades. 3 out of the 5 trends are in the field of medical devices. Additionally, 1